ZEVRA THERAPEUTICS, INC.

Analyst Reco. Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			5-day change	1st Jan Change
4.89 ^USD	+1.45%		-5.14%	-25.34%

05-08	Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	MT
05-08	Transcript : Zevra Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

William Blair Starts Zevra Therapeutics With Outperform Rating	03-12	MT
HC Wainwright Adjusts Price Target on Zevra Therapeutics to $15 From $10, Keeps Buy Rating	12-28	MT
Canaccord Genuity Adjusts Price Target on Zevra Therapeutics to $20 From $19, Keeps Buy Rating	15/08/23	MT
Maxim Starts Zevra Therapeutics at Buy With $12 Price Target	17/03/23	MT
Cantor Fitzgerald Starts KemPharm at Overweight With $20 Price Target	17/11/22	MT
KemPharm Shares Rise After Canaccord Genuity Initiates Coverage	15/09/22	MT
Canaccord Genuity Starts KemPharm at Buy With $20 Price Target	15/09/22	MT
HC Wainwright Cuts KemPharm's Price Target to $10 From $11, Reiterates Buy Rating	17/08/22	MT
HC Wainwright Upgrades KemPharm to Buy From Neutral, Adjusts Price Target to $11 From $10	31/01/22	MT
KEMPHARM : HC Wainwright Adjusts Price Target on KemPharm to $10 From $12, Maintains Neutral Rating	09/04/21	MT
KEMPHARM : HC Wainwright Downgrades KemPharm to Neutral From Buy, Adjusts Price Target to $12 From $24	04/03/21	MT
KEMPHARM : Roth Capital Starts KemPharm at Buy With $28 Price Target	25/01/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer